Skip to main content

Table 1 Anti-HBs immune response in subjects according to their pre-challenge dose serostatus (ATP cohort for immunogenicity)

From: Five years follow-up following two or three doses of a hepatitis B vaccine in adolescents aged 11-15 years: a randomised controlled study

Group

Pre-challenge status (mIU/mL)

N

≥10 mIU/mL

≥100 mIU/mL

GMC

% or Value (95% CI)

HBV_2D

<3.3

6

100 (54.1 - 100)

66.7 (22.3 - 95.7)

277.5 (24.7 - 3117.3)

 

3.3 to <10

6

100 (54.1 - 100)

83.3 (35.9 - 99.6)

821.7 (142.8 - 4729.5)

 

10 to 100

26

100 (86.8 - 100)

100 (86.8 - 100)

6117.3 (2875.1 - 13015.7)

 

≥100

15

100 (78.2 - 100)

100 (78.2 - 100)

49745.4 (24663.9 - 100332.9)

HBV_3D

<3.3

1

100 (2.5 - 100)

0.0 (0.0 - 97.5)

37.4 (-)

 

3.3 to <10

0

-

-

-

 

10 to 100

9

100 (66.4 - 100)

100 (66.4 - 100)

6048.5 (2414.6 - 15150.9)

 

≥100

11

100 (71.5 - 100)

100 (71.5 - 100)

65723.7 (34920.1 - 123699.6)

Pooled

<3.3

7

100 (59.0 - 100)

57.1 (18.4 - 90.1)

208.4 (26.3 - 1648.7)

 

3.3 to <10

6

100 (54.1 - 100)

83.3 (35.9 - 99.6)

821.7 (142.8 - 4729.5)

 

10 to 100

35

100 (90.0 - 100)

100 (90.0 - 100)

6099.5 (3396.3 - 10954.1)

 

≥100

26

100 (86.8 - 100)

100 (86.8 - 100)

55967.0 (35483.1 - 88276.2)

  1. N = number of subjects with available results; 95% CI = exact 95% confidence interval
  2. GMC = geometric mean concentrations